top of page

Anushree Chatterjee, Ph. D.

co-founder, Chairperson, CEO

Mission: Making antisense therapeutics and precision medicine an accessible treatment option for patient to cure diseases.

  • Linkedin

My Story

Dr. Anushree Chatterjee has 15+ years of experience in synthetic and systems biology.  She is the co-inventor of Sachi's drug discovery technology. She received her Bachelors and Masters of Technology in Chemical Engineering from Indian Institute of Technology Delhi in 2006. She earned her Ph.D. in Chemical engineering at the University of Minnesota on understanding molecular mechanisms of antibiotic resistance transfer in clinical superbugs in 2011. She was a postdoctoral research fellow at the Theoretical Biology and Biophysics group at Los Alamos National Laboratory studying gene regulation of hepatitis C virus till 2012.
In 2013, Anushree joined the faculty at University of Colorado Boulder. She has published 50+ papers in high-impact peer-reviewed journals, given 55 invited talks, and 70+ contributed talks. Anushree has received numerous awards including the DARPA Young Faculty Award, ACS Infectious Diseases Young Investigator Award, New Inventor of the Year award, Provost’s Faculty Achievement award, and the prestigious William M. keck Foundation grant award. Anushree’s research has been featured by academic and federal institutions such as the Material Research Society, Faculty of 1000, and the National Science Foundation, as well as popular national and international media outlets including BBC, CGTN America, and Voice of America. She has also founded/co-founded two Biotech startup companies, the non-profit organization Antimicrobial Regeneration Consortium Labs. She also an Associate Professor of Chemical and Biological Engineering at University of Colorado Boulder.

Selected Publications

  • ​​Colleen McCollum, Colleen Courtney, Nolan O'Connor, Thomas Aunins, Yuchen Ding, Tristan Jordan, Keegan Rogers, Stephen Brindley, Jared Brown, Prashant Nagpal, and, Anushree Chatterjee* (2022). Nanoligomers targeting human miRNA for treatment of severe COVID-19 are safe and nontoxic in mice. ACS Biomaterials Science and Engineering 8(7) 3087-3106. 

  • Colleen Rei McCollum, Colleen M Courtney, Nolan J O'Connor, Thomas R Aunins, Tristan X Jordan, Keegan Rogers, Stephen Brindley, Jared M Brown, Prashant Nagpal, Anushree Chatterjee* (2023). Safety and biodistribution of NanoligomersTM targeting SARS-CoV-2 genome for treatment of COVID-19. ACS Biomaterials Science and Engineering 9(3):1656-1671. ​

  • Colleen M Courtney, Sadhana Sharma, Christina Fallgren, Michael M Weil, Anushree Chatterjee, Prashant Nagpal* (2022). Reversing Radiation-Induced Immunosuppression Using a New Therapeutic Modality. Life Sciences in Space Research (In press).

  • Colleen R. McCollum, John R. Bertram, Prashant Nagpal, and Anushree Chatterjee* (2021). Photoactivated indium phosphide quantum dots treat multi-drug resistant bacterial abscesses in vivo. ACS Applied Materials & Interfaces 13(26), 30404–30419.

  • Thomas R. Aunins, Keesha E. Erickson, Anushree Chatterjee* (2020). Transcriptome-based design of antisense inhibitors potentiates carbapenem efficacy in CRE E. coli. Proceedings of the National Academy of Sciences 117(48) 30699-30709.

  •  McDonald et al. (2021). Role of miR-2392 in driving SARS-CoV-2 infection. Cell Reports. Volume 37, Issue 3, 109839.

  • Colleen M. Courtney, Samuel Goodman, Jessica Mc Daniel, Nancy Madinger, Anushree Chatterjee*, and Prashant Nagpal* (2016). "Photoexcited Quantum Dots for Killing Multi-Drug Resistant Bacteria." Nature Materials 15, 529-534. 

bottom of page